{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:09:22Z","timestamp":1786468162006,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ygyno.2013.12.018","type":"journal-article","created":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T14:02:13Z","timestamp":1387375333000},"page":"526-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"132","author":[{"given":"Lainie P.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1910-4523","authenticated-orcid":false,"given":"Mark S.","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Landrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Goodheart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.12.018_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0010","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-Met signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0015","first-page":"1997","article-title":"Expression of the Met\/HGF receptor in normal and neoplastic human tissues","volume":"6","author":"Di Renzo","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jcp.21183","article-title":"The MET receptor tyrosine kinase in invasion and metastasis","volume":"213","author":"Benvenuti","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0025","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1038\/35083116","article-title":"Pathway specificity for Met signalling","volume":"3","author":"Comoglio","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0030","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1097-2765(01)00261-1","article-title":"Coupling Met to specific pathways results in distinct developmental outcomes","volume":"7","author":"Maina","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2013.12.018_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2121-6-8","article-title":"Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells","volume":"6","author":"Rahman","year":"2005","journal-title":"BMC Cell Biol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0040","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0092-8674(01)00567-0","article-title":"A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth","volume":"107","author":"Trusolino","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0045","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jcp.21240","article-title":"Epithelial\u2013mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm","volume":"213","author":"Ahmed","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0050","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1091\/mbc.01-10-0477","article-title":"Crk adapter proteins promote an epithelial\u2013mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions","volume":"13","author":"Lamorte","year":"2002","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0055","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1083\/jcb.111.5.2097","article-title":"Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells","volume":"111","author":"Weidner","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V","article-title":"Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells","volume":"83","author":"Sowter","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0303-7207(03)00067-4","article-title":"Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinomas via Ras mediated pathway","volume":"202","author":"Ueoka","year":"2003","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1083\/jcb.121.1.145","article-title":"The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor\/hepatocyte growth factor in epithelial cells","volume":"121","author":"Weidner","year":"1993","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0075","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.2910580507","article-title":"Overexpression of the Met\/HGF receptor in ovarian cancer","volume":"58","author":"Di Renzo","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0002-9440(10)65130-9","article-title":"Comparison of c-met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy","volume":"155","author":"Huntsman","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I","article-title":"Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met","volume":"73","author":"Corps","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1006\/gyno.2000.5877","article-title":"Hepatocyte growth factor promotes in vitro scattering and morphogenesis of human cervical carcinoma cells","volume":"78","author":"Wong","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0095","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.onc.1204253","article-title":"Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?","volume":"20","author":"Wong","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0100","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-06-1147","article-title":"c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion","volume":"67","author":"Sawada","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0105","first-page":"1013","article-title":"The roles of hepatocyte growth factor\/scatter factor and met receptor in human cancers","volume":"5","author":"To","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors","volume":"16","author":"Gordon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0120","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2011.02.013","article-title":"A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies","volume":"121","author":"Usha","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/neuonc\/noq198","article-title":"A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma","volume":"13","author":"Wen","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0135","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2013.12.018_bb0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813013826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813013826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T00:27:21Z","timestamp":1538958441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813013826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0090825813013826"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}